Search

LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct.

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV.

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the U.S.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept.

Key Updates

LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases

Cet accès s'appuie sur une analyse intermédiaire positive des données cliniques et des données précliniques à ce jour